Lung Cancer Stage Four 10 Years Cancer-Free Through Non-toxic Alternative Cancer Treatment

          -- Recurrent lung cancer responds to Integrative Immunotherapy

          Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.

          To view the multimedia assets associated with this release, please visit http://www.multivu.com/mnr/65511-issels-integrative-immunotherapy-non-toxic-treatment-lung-cancer

          (Photo: http://photos.prnewswire.com/prnh/20140211/MM56889)

          While several leading cancer centers have only begun introducing immunotherapy, Issels has been a leader in Integrative Immunotherapy for decades.

          In 1951, Dr. Josef M. Issels, MD founded the world's first hospital specializing in integrative oncology based on integrative immunotherapy. He achieved documented complete long-term remissions of standard therapy-resistant cancers. In view of his expertise, Dr. Issels was invited to serve as an expert member of the German Federal Government Commission in the Fight against Cancer from 1981 until his retirement in 1987.

          Issels Integrative Immunotherapy distinguishes itself decisively from mere vaccine administration by integrating specific autologous cancer vaccines, such as Dendritic Cell Vaccine, as well as autologous Lymphokine-Activated Killer (LAK) Cells and activated autologous Natural Killer (NK) Cells, which work on the cellular level of the immune system, into a comprehensive immunobiologic core treatment addressing the tumor microenvironment. The Issels strategy enhances the body's complex defense mechanisms, potentiating the efficacy of vaccine and cell therapies, as seen in the case of Jim Gibson.

          In March 2003, Jim Gibson commenced the non-toxic Issels Integrative Immunotherapy including dendritic cell vaccine for his recurring small cell lung cancer, which is the most lethal kind of all lung cancers. After 4 weeks of exclusive Issels Immunotherapy he achieved complete tumor remission and is still cancer free and very active 10 years later without any standard therapy.

          Nicole Tupper describes her experience with solely using Issels immunobiologic core treatment for her metastatic adenocarcinoma of the appendix: "I found Issels as a last resort. When I came here, I was a mess...and all of a sudden I started making leaps and bounds. In my last ultrasound my 12-centimeter tumor completely disappeared and all my other abdominal tumors reduced to less than half."

          Nicole underwent the Issels immunobiologic core treatment at the Issels U.S. out-patient facility, where patients can also receive advanced genetically targeted cancer therapies.

          The Issels medical team brings decades of expertise in providing highly personalized comprehensive immunotherapy programs. Vaccine and cell therapies are administered at the most modern facility of the largest private hospital network of 22 hospitals in Mexico, which meets the highest U.S. and international standards. It is the only full-service hospital in Mexico offering integrative medicine.

          Visit the Issels website www.issels.com to learn more about the Issels treatment programs and facilities, or watch more videos of patient testimonials.

 


ข่าวLung Cancer+o:prnusวันนี้

Nearly 80% of Doctors Worldwide Mistakenly Believe Nicotine Causes Lung Cancer, Thwarting Efforts to Help One Billion Smokers Quit

Survey of more than 15,000 physicians in 11 countries uncovers need for further educationThe Foundation for a Smoke-Free World invites researchers to propose new analysis & educational programs On average, nearly 77% of doctors mistakenly believe nicotine causes lung cancer and 78% believe it causes atherosclerosis. While on average 87% of doctors at least moderately agree that helping patients quit smoking is a priority, lack of training and nicotine knowledge adversely impacts quitting and

วันมะเร็งปอดโลกซึ่งตรงกับวันที่ตรงกับวันท... เสวนาวันมะเร็งปอดโลก: ดูแลปอด ดูแลใจ เพื่อผู้ป่วยมะเร็งปอด — วันมะเร็งปอดโลกซึ่งตรงกับวันที่ตรงกับวันที่ 1 สิงหาคมของทุกปี จัดขึ้นเพื่อรณรงค์ให้คนทั่วโลกห...

Thai Lung Cancer Group (TLCG) organizes t... TLCG organizes the "Innovations for Thai Lung Cancer Patients 2020" with the launch "LungAndMe" — Thai Lung Cancer Group (TLCG) organizes the "Innovations...

Innovations for Thai Lung Cancer Patients... Innovations for Thai Lung Cancer Patients 2020 launch "LungAndMe" — Innovations for Thai Lung Cancer Patients 2020: evolving treatments for lung cancerBri...

Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Not intended for UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial...

โรงพยาบาลวัฒโนสถ ขอเชิญชวนผู้ที่สนใจตรวจส... โรงพยาบาลวัฒโนสถเชิญชวนตรวจมะเร็งปอดเนื่องในวันงดสูบบุหรี่โลก (Package Lung Cancer Early Detection ) — โรงพยาบาลวัฒโนสถ ขอเชิญชวนผู้ที่สนใจตรวจสุขภาพ "ป้อ...

Registration & Abstract Submission Open for IASLC's 2016 World Conference on Lung Cancer in Vienna

Largest Worldwide Lung Cancer Research Organization Invites Global Collaborators to Attend Registration and abstract submission is now open for the International Association for the Study of Lung Cancer...

Global Strategic Partners Merck and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer

Not intended for UK-based media First of several registration trials expected to start in 2015 for the alliance between Merck and Pfizer Initiation and first...

Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer

Not intended for UK-based media Merck announced today that its biopharmaceutical division Merck Serono will discontinue the clinical development program of its investigational MUC1...